Literature DB >> 27163336

How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.

Albert T Gacerez1, Benjamine Arellano1, Charles L Sentman1.   

Abstract

Chimeric antigen receptor (CAR) T cells have been developed to treat tumors and have shown great success against B cell malignancies. Exploiting modular designs and swappable domains, CARs can target an array of cell surface antigens and, upon receptor-ligand interactions, direct signaling cascades, thereby driving T cell effector functions. CARs have been designed using receptors, ligands, or scFv binding domains. Different regions of a CAR have each been found to play a role in determining the overall efficacy of CAR T cells. Therefore, this review provides an overview of CAR construction and common designs. Each CAR region is discussed in the context of its importance to a CAR's function. Additionally, the review explores how various engineering strategies have been applied to CAR T cells in order to regulate CAR T cell function and activity. J. Cell. Physiol. 231: 2590-2598, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27163336      PMCID: PMC4993661          DOI: 10.1002/jcp.25419

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  89 in total

1.  Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain.

Authors:  C Romeo; M Amiot; B Seed
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

2.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

3.  T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term.

Authors:  M Chmielewski; G Rappl; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2012-03-01       Impact factor: 5.250

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

5.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Authors:  Hillary G Caruso; Lenka V Hurton; Amer Najjar; David Rushworth; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Dean A Lee; Amy B Heimberger; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

6.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

7.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

Authors:  C Imai; K Mihara; M Andreansky; I C Nicholson; C-H Pui; T L Geiger; D Campana
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

8.  OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells.

Authors:  Andreas A Hombach; Johannes Heiders; Marcel Foppe; Markus Chmielewski; Hinrich Abken
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

9.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

10.  High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

Authors:  R C Lynn; Y Feng; K Schutsky; M Poussin; A Kalota; D S Dimitrov; D J Powell
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

View more
  12 in total

1.  [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].

Authors:  Yao-Jun Peng; Qi-Yan Wu; Hong-Yu Liu; Jian Zhao; Hua-Feng Wei
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

2.  Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.

Authors:  Zhijing An; Yi Hu; Yue Bai; Can Zhang; Chang Xu; Xun Kang; Shoubo Yang; Wenbin Li; Xiaosong Zhong
Journal:  Oncoimmunology       Date:  2021-08-16       Impact factor: 8.110

Review 3.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 4.  The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

Authors:  Daniel Feinberg; Barry Paul; Yubin Kang
Journal:  Cell Immunol       Date:  2019-08-13       Impact factor: 4.868

5.  Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Authors:  Joana M Murad; Susanne H Baumeister; Lillian Werner; Heather Daley; Hélène Trébéden-Negre; Jake Reder; Charles L Sentman; David Gilham; Frederic Lehmann; Sarah Snykers; Marie-Louise Sentman; Terri Wade; Adam Schmucker; Michael W Fanger; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cytotherapy       Date:  2018-06-29       Impact factor: 5.414

Review 6.  Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.

Authors:  Taewoong Choi; Yubin Kang
Journal:  Pharmacol Ther       Date:  2021-09-25       Impact factor: 13.400

7.  T-bet promotes potent antitumor activity of CD4+ CAR T cells.

Authors:  Albert T Gacerez; Charles L Sentman
Journal:  Cancer Gene Ther       Date:  2018-03-07       Impact factor: 5.987

Review 8.  CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Authors:  Kristen B Long; Regina M Young; Alina C Boesteanu; Megan M Davis; J Joseph Melenhorst; Simon F Lacey; David A DeGaramo; Bruce L Levine; Joseph A Fraietta
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

9.  APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.

Authors:  Qunyi Peng; Xiongpeng Zhu; Chuntuan Li; Pengliang Xin; Yan Zheng; Shengquan Liu
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

10.  A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells.

Authors:  Darin Bloemberg; Tina Nguyen; Susanne MacLean; Ahmed Zafer; Christine Gadoury; Komal Gurnani; Anindita Chattopadhyay; Josée Ash; Julie Lippens; Doreen Harcus; Martine Pagé; Annie Fortin; Robert A Pon; Rénald Gilbert; Anne Marcil; Risini D Weeratna; Scott McComb
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-31       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.